Raúl Martín-Ruiz

Health is the level of functional or metabolic efficiency of a living organism. In humans it is the ability of individuals or communities to adapt and self-manage when facing physical, mental or social challenges.

Kynexis is advancing precision therapeutics for brain diseases by taking a biomarker-based approach to advance a potential first-in-class treatment for cognitive impairment associated with schizophrenia (CIAS). By harnessing large data to identify and stratify patients based on the underlying causal human. biology of the disease, Kynexis is targeting KAT-II, a key enzyme in the kynurenine pathway. The company’s lead candidate, KYN-5356, is a first-in-class small molecule that is potent and highly selective for KAT-II.

Synendos Therapeutics AG is a biopharmaceutical company founded in April 2019 as a spin-off of the University of Bern. Synendos develops an innovative therapeutic approach based upon first-in-class inhibitors (small molecules) that modulate a new drug target (not yet published). The inhibitors were designed and developed at the University of Bern starting from an in silico screening of 12 million compounds which was followed by a thorough med chem programme in collaboration with a CRO. The inhibitors act with a new mechanism of action that enables restoration of the natural function of the brain by rebalancing altered neurotransmission in different areas of the bran. Our mission is to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders.

MedLumics is a medical device company with the goal of taking the latest technological and scientific developments in biophotonics and turning them into innovative and quality products to improve the quality of life. Our work is focused on one of the most successful light-based diagnostic techniques, Optical Coherence Tomography, which is currently seeing rapid expansion and growth. Our disruptive technological advantages allow us to offer unique medical solutions and to develop the clinical applications of this imaging modality. MedLumics, Enlightening Healthcare

Prexton Therapeutics SA is a pharmaceuticals company based out of 14 Ch. des Aulx, Plan-les-Ouates, Geneva, Switzerland.

Health is the level of functional or metabolic efficiency of a living organism. In humans it is the ability of individuals or communities to adapt and self-manage when facing physical, mental or social challenges.

Kynexis is advancing precision therapeutics for brain diseases by taking a biomarker-based approach to advance a potential first-in-class treatment for cognitive impairment associated with schizophrenia (CIAS). By harnessing large data to identify and stratify patients based on the underlying causal human. biology of the disease, Kynexis is targeting KAT-II, a key enzyme in the kynurenine pathway. The company’s lead candidate, KYN-5356, is a first-in-class small molecule that is potent and highly selective for KAT-II.

Synendos Therapeutics AG is a biopharmaceutical company founded in April 2019 as a spin-off of the University of Bern. Synendos develops an innovative therapeutic approach based upon first-in-class inhibitors (small molecules) that modulate a new drug target (not yet published). The inhibitors were designed and developed at the University of Bern starting from an in silico screening of 12 million compounds which was followed by a thorough med chem programme in collaboration with a CRO. The inhibitors act with a new mechanism of action that enables restoration of the natural function of the brain by rebalancing altered neurotransmission in different areas of the bran. Our mission is to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders.

MedLumics is a medical device company with the goal of taking the latest technological and scientific developments in biophotonics and turning them into innovative and quality products to improve the quality of life. Our work is focused on one of the most successful light-based diagnostic techniques, Optical Coherence Tomography, which is currently seeing rapid expansion and growth. Our disruptive technological advantages allow us to offer unique medical solutions and to develop the clinical applications of this imaging modality. MedLumics, Enlightening Healthcare